NCT07132333 Molecular Inflammation Board at the Center for Personalized Medicine
| NCT ID | NCT07132333 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | Psoriasis (PsO) |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-11-16 |
| Primary Completion | 2032-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-11-16 with a primary completion date of 2032-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Molecular Inflammation Board at the Center for Personalized Medicine
Eligibility Criteria
Inclusion Criteria: * Chronic inflammatory disorder (PsO, PsA, SpA, IBD) * Given informed consent * 18 years of age Exclusion Criteria: * No capacity to consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07132333 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis (PsO). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07132333 currently recruiting?
Yes, NCT07132333 is actively recruiting participants. Contact the research team at zpm-meb@med.uni-tuebingen.de for enrollment information.
Where is the NCT07132333 trial being conducted?
This trial is being conducted at Tübingen, Germany.
Who is sponsoring the NCT07132333 clinical trial?
NCT07132333 is sponsored by University Hospital Tuebingen. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.